TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

26 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

06 Jun 2023 15:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

02 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

25 May 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

24 May 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions

22 May 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

15 May 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference

09 May 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

03 May 2023 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

27 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

27 Mar 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

02 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

02 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

12 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

05 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

23 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Announces Pricing of $75 Million Public Offering

20 Dec 2022 18:39:56 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

20 Dec 2022 07:05:00 By Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

19 Dec 2022 15:31:04 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

01 Dec 2022 15:05:00 By Nasdaq GlobeNewswire